Pure Global
NCT06069570

Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Stage 4 Metastatic NSCLC

Phase 1 Trial Evaluating the Safety and Tolerability of Gamma Delta T-Cell Infusions in Combination With Low Dose Radiotherapy in Subjects With Stage 4 Metastatic Non-Small Cell Lung Cancer
Kiromic BioPharma Inc.·Phase 1·ClinicalTrials.gov·biologicalNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Carcinoma, Non-Small-Cell Lung
Drug/Device/Intervention
KB-GDT-01
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
Kiromic BioPharma Inc.
Timeline & enrollment
Phase
Phase 1
Start date
Dec 01, 2023
End date
Jan 01, 2027
Enrollment
48 participants
Primary outcome

Number of participants with Adverse Events (AE) and/or Dose Limiting Toxicities (DLT) as a Measurement of Safety and Tolerability of KB-GDT-01 in Combination with LDRT

Summary

This is a clinical trial studying intravenous infusions of allogeneic gamma delta T cells
 after receiving low dose radiotherapy in participants with metastatic non-small cell lung
 cancer to evaluate the safety and efficacy of combining immunotherapy with radiation therapy.

ICD-10 classifications
Carcinoma in situ: Bronchus and lungSecondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06069570
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06069570 through Pure Global AI's free database. This Phase 1 trial is sponsored by Kiromic BioPharma Inc. and is currently Not yet recruiting. The study focuses on Carcinoma, Non-Small-Cell Lung. Target enrollment is 48 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.